Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.

Lin P, Ren Y, Yan X, Luo Y, Zhang H, Kesarwani M, Bu J, Zhan D, Zhou Y, Tang Y, Zhu S, Xu W, Zhou X, Mei C, Ma L, Ye L, Hu C, Azam M, Ding W, Jin J, Huang G, Tong H.

Haematologica. 2019 Mar;104(3):485-496. doi: 10.3324/haematol.2018.197749. Epub 2018 Sep 27.

2.

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.

Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E.

Cancer. 2006 Mar 1;106(5):1099-109.

3.

A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.

Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y.

Cancer. 1996 Aug 1;78(3):422-6.

PMID:
8697386
4.
5.

Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.

Liu Z, Chen J, Wang H, Ding K, Li Y, de Silva A, Sehgal V, Burbano JL, Sundararaj R, Gamage J, Audu V, Fu R.

Am J Transl Res. 2017 Dec 15;9(12):5631-5642. eCollection 2017.

6.

[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Apr;17(2):459-63. Chinese.

PMID:
19379588
7.

Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

Ruutu T, Hänninen A, Järventie G, Koistinen P, Koivunen E, Kätkä K, Nousiainen T, Oksanen K, Pelliniemi TT, Remes K, Timonen T, Volin L, Elonen E.

Leuk Res. 1997 Feb;21(2):133-8.

PMID:
9112430
8.

Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.

Karathedath S, Rajamani BM, Musheer Aalam SM, Abraham A, Varatharajan S, Krishnamurthy P, Mathews V, Velayudhan SR, Balasubramanian P.

PLoS One. 2017 May 15;12(5):e0177227. doi: 10.1371/journal.pone.0177227. eCollection 2017.

9.

[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].

Ma XR, Wang J, Zhang WG, Chen YX, Cao XM, He AL, Liu J, Wang JL, Gu LF, Lei B, Zhang PY, Zhao WH, Yang Y, Wang FX, Xu Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Apr;23(2):369-74. doi: 10.7534/j.issn.1009-2137.2015.02.014. Chinese.

PMID:
25948187
10.
11.

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

Prébet T, Ducastelle S, Debotton S, Stamatoullas A, Deconinck E, Fruchart C, Gratecos N, Ifrah N, Dreyfus F, Fenaux P, Wattel E; Groupe Français des Myélodysplasies (GFM), France.

Hematol J. 2004;5(3):209-15.

PMID:
15167906
12.

Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1563-9. doi: 10.1007/s00432-011-1020-2. Epub 2011 Aug 4.

PMID:
21845438
13.

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.

Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ.

Br J Haematol. 1997 Dec;99(4):939-44.

PMID:
9432047
14.

A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.

Hu KX, Sun QY, Guo M, Qiao JX, Yu CL, Qiao JH, Dong Z, Sun WJ, Zuo HL, Huang YJ, Cai B, Ai HS.

Stem Cells Transl Med. 2016 Apr;5(4):524-9. doi: 10.5966/sctm.2015-0196. Epub 2016 Feb 2.

15.
16.

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).

de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, Amadori S, Willemze R, Muus P, Baron F.

Ann Hematol. 2015 Dec;94(12):1981-9. doi: 10.1007/s00277-015-2486-9. Epub 2015 Sep 26.

17.

Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.

Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D.

Cancer Chemother Pharmacol. 2012 Feb;69(2):485-94. doi: 10.1007/s00280-011-1722-9. Epub 2011 Aug 13.

PMID:
21842204
19.

Luteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling.

Sabzichi M, Hamishehkar H, Ramezani F, Sharifi S, Tabasinezhad M, Pirouzpanah M, Ghanbari P, Samadi N.

Asian Pac J Cancer Prev. 2014;15(13):5311-6.

20.

Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.

Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N, Jacobsen BB.

Leukemia. 1996 Aug;10(8):1269-73.

PMID:
8709630

Supplemental Content

Support Center